Sales Already Growing As Vascepa Secures Cardio Approval
Fish Oil Derivative Seen As Biggest Advance In Decades
Company forecasts 2020 sales as high as $700m after regulator grants broad label.
You may also be interested in...
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
Amarin has confirmed that it plans to take its legal battle over Vascepa all the way to the US Supreme Court, as it seeks to overturn a ruling that has already allowed Hikma to launch its generic rival.
Hikma has launched its US rival to Vascepa, after the US Court of Appeals for the Federal Circuit refused a request by Amarin for an “en banc” rehearing of key litigation.